Chr. Hansen, leading global bioscience company, realizes solid organic revenue growth of 10 % in the first three months of the financial year 2018/19 corresponding to 6 % reported growth due to adverse currency impacts: Food Cultures & Enzymes 10 %, Health & Nutrition 17 % and Natural Colours 6 %. Ebit before special items increased by 9 % to EUR 71 m, corresponding to an Ebit margin before special items of 26.3 % which was up 0.9 %-point compared to last year. The overall outlook for 2018/19 remains unchanged.